Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Original Article

TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD

Baokai Sun, Xiaoqian Ding, Jie Tan, Jie Zhang, Xueru Chu, Shuimi Zhang, Shousheng Liu, Zhenzhen Zhao, Shiying Xuan, Yongning Xin, Likun Zhuang

Clin Mol Hepatol. 2024;30(4):863-882. Published online July 26, 2024

DOI: https://doi.org/10.3350/cmh.2024.0268

View: 2538 Download: 260 Web of Science: 5 Crossref: 3

Letter to the Editor

Changing from NAFLD to MASLD: Similar cumulative incidence of reflux esophagitis between NAFLD and MASLD

Shuhei Fukunaga, Michita Mukasa, Dan Nakano, Tsubasa Tsutsumi, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(1):121-123. Published online December 4, 2023

DOI: https://doi.org/10.3350/cmh.2023.0437

View: 2739 Download: 90 Web of Science: 9 Crossref: 9

Review

Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments

Sang Bong Ahn

Clin Mol Hepatol. 2023;29(Suppl):S150-S156. Published online January 25, 2023

DOI: https://doi.org/10.3350/cmh.2022.0362

View: 5470 Download: 253 Web of Science: 10 Crossref: 13

Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future

Asako Nogami, Masato Yoneda, Michihiro Iwaki, Takashi Kobayashi, Yasushi Honda, Yuji Ogawa, Kento Imajo, Satoru Saito, Atsushi Nakajima

Clin Mol Hepatol. 2023;29(Suppl):S123-S135. Published online December 12, 2022

DOI: https://doi.org/10.3350/cmh.2022.0357

View: 5565 Download: 225 Web of Science: 13 Crossref: 14

Original Article

Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity

Hong-Kyu Kim, Sung-Jin Bae, Min Jung Lee, Eun Hee Kim, Hana Park, Hwi Seung Kim, Yun Kyung Cho, Chang Hee Jung, Woo Je Lee, Jaewon Choe

Clin Mol Hepatol. 2023;29(4):987-1001. Published online July 5, 2023

DOI: https://doi.org/10.3350/cmh.2023.0035

View: 6143 Download: 326 Web of Science: 24 Crossref: 27

Editorial

From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials

Ming-Lun Yeh, Ming-Lung Yu

Clin Mol Hepatol. 2023;29(4):969-972. Published online September 18, 2023

DOI: https://doi.org/10.3350/cmh.2023.0359

View: 3538 Download: 183 Web of Science: 11 Crossref: 12

The latest evidence on the impact of fatty liver on liver-related outcomes and mortality in chronic hepatitis B

Xianhua Mao, Lung Yi Mak, Wai-Kay Seto

Clin Mol Hepatol. 2023;29(3):690-692. Published online May 30, 2023

DOI: https://doi.org/10.3350/cmh.2023.0173

View: 2989 Download: 109 Web of Science: 1 Crossref: 1

Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future

Lynna Alnimer, Mazen Noureddin

Clin Mol Hepatol. 2023;29(2):394-397. Published online April 1, 2023

DOI: https://doi.org/10.3350/cmh.2023.0104

View: 3901 Download: 94 Web of Science: 2 Crossref: 1

Original Article

Gut-derived lipopolysaccharide promotes alcoholic hepatosteatosis and subsequent hepatocellular carcinoma by stimulating neutrophil extracellular traps through toll-like receptor 4

Yang Liu, Xin Zhang, Shuo Chen, Jiazhong Wang, Shuo Yu, Yiming Li, Meng Xu, Harouna Aboubacar, Junhui Li, Tao Shan, Jixin Wang, Gang Cao

Clin Mol Hepatol. 2022;28(3):522-539. Published online May 4, 2022

DOI: https://doi.org/10.3350/cmh.2022.0039

View: 6388 Download: 204 Web of Science: 27 Crossref: 24

Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis

Gang Xu, Yu-Min Wang, Miao-Miao Ying, Sui-Dan Chen, Zong-Rui Li, Hong-Lei Ma, Ming-Hua Zheng, Jian Wu, Chunming Ding

Clin Mol Hepatol. 2021;27(2):329-345. Published online January 20, 2021

DOI: https://doi.org/10.3350/cmh.2020.0261

View: 8502 Download: 243 Web of Science: 17 Crossref: 17

Liver Imaging

Chemotherapy induced liver abnormalities: an imaging perspective

Ankush Sharma, Roozbeh Houshyar, Priya Bhosale, Joon-Il Choi, Rajesh Gulati, Chandana Lall

Clin Mol Hepatol. 2014;20(3):317-326. Published online September 25, 2014

DOI: https://doi.org/10.3350/cmh.2014.20.3.317

View: 16818 Download: 330 Web of Science: 65 Crossref: 63

Review

KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease

The Korean Association for the Study of the Liver (KASL)

Clin Mol Hepatol. 2013;19(4):325-348. Published online December 28, 2013

DOI: https://doi.org/10.3350/cmh.2013.19.4.325

View: 15041 Download: 164 Crossref: 95

5

Fatty Liver

So Young Jin

Clin Mol Hepatol. 2006;12(1):112-115. Published online January 1, 1970

View: 2557 Download: 13

1 |

Viewed By 7419	MAFLD: How is it different from NAFLD?
Viewed By 7020	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 5609	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 5362	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4790	Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease

Cited By 298	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 270	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 186	MAFLD: How is it different from NAFLD?
Cited By 93	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 92	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Search